New injection shows promise for reducing excessive drooling
NCT ID NCT01994109
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 study tested whether injections of MYOBLOC (a botulinum toxin type B) into the salivary glands can safely reduce troublesome drooling in adults. 187 participants received either MYOBLOC or a placebo. The main goals were to measure changes in saliva flow and overall improvement at 4 weeks. Results showed that MYOBLOC effectively decreased saliva production and improved symptoms compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MYOBLOC (rimabotulinumtoxinB, botulinum toxin type B)
- What this could lead to
- If it works, this could provide a safe and effective treatment option for adults with troublesome drooling due to various medical conditions.
- What could go wrong
- This is a completed Phase 3 trial, so results are more reliable, but individual responses may vary and there are risks like dry mouth or injection site reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SIALORRHEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Loma Linda, California, 92354, United States
-
Study site
Los Angeles, California, 90033, United States
-
Study site
National City, California, 91950, United States
-
Study site
Aurora, Colorado, 80045, United States
-
Study site
Washington D.C., District of Columbia, 20007, United States
-
Study site
Boca Raton, Florida, 33486, United States
-
Study site
Port Charlotte, Florida, 33980, United States
-
Study site
Carmel, Indiana, 46032, United States
-
Study site
Baltimore, Maryland, 21287, United States
-
Study site
Elkridge, Maryland, 21075, United States
-
Study site
Detroit, Michigan, 48334, United States
-
Study site
St Louis, Missouri, 63110, United States
-
Study site
Edison, New Jersey, 08818, United States
-
Study site
Albany, New York, 12208, United States
-
Study site
New York, New York, 10003, United States
-
Study site
Cincinnati, Ohio, 45219, United States
-
Study site
Tulsa, Oklahoma, 74136, United States
-
Study site
Port Royal, South Carolina, 29935, United States
-
Study site
Cordova, Tennessee, 38018, United States
-
Study site
Houston, Texas, 77030, United States
-
Study site
San Antonio, Texas, 78229, United States
-
Study site
Salt Lake City, Utah, 84132, United States
-
Study site
Kirkland, Washington, 98034, United States
-
Study site
Tacoma, Washington, 98409, United States
-
Study site
Irkutsk, Irkutsk Oblast, 664079, Russia
-
Study site
Vsevolozhsk, Leningradskaya Oblast', 188643, Russia
-
Study site
Saint Petersburg, Petrodvorets, 198510, Russia
-
Study site
Krasnoyarsk, 660037, Russia
-
Study site
Dnipropetrovsk, 49027, Ukraine
-
Study site
Ivano-Frankivsk, 76008, Ukraine
-
Study site
Kharkiv, 61068, Ukraine
-
Study site
Lviv, 79010, Ukraine
-
Study site
Rivne, 33010, Ukraine
-
Study site
Uzhhorod, 88018, Ukraine
More trials for these conditions
Other studies related to the condition(s) this trial covers.